Linzagolix for treating symptoms of endometriosis (TA1067)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 June 2025
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 April 2025
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 August 2024
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 October 2022